AU2020329290A1 - Engineered interleukin-2 receptor beta agonists - Google Patents

Engineered interleukin-2 receptor beta agonists Download PDF

Info

Publication number
AU2020329290A1
AU2020329290A1 AU2020329290A AU2020329290A AU2020329290A1 AU 2020329290 A1 AU2020329290 A1 AU 2020329290A1 AU 2020329290 A AU2020329290 A AU 2020329290A AU 2020329290 A AU2020329290 A AU 2020329290A AU 2020329290 A1 AU2020329290 A1 AU 2020329290A1
Authority
AU
Australia
Prior art keywords
engineered
polypeptide
seq
substitution
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020329290A
Other languages
English (en)
Inventor
Yan Chen
Samuel Clement HASSAN
Ning Jiang
Nathan KALLEN
Jenna NGUYEN
Christina SWANSON
Kehao Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elpis Biopharmaceuticals Corp
Original Assignee
Elpis Biopharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpis Biopharmaceuticals Corp filed Critical Elpis Biopharmaceuticals Corp
Publication of AU2020329290A1 publication Critical patent/AU2020329290A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020329290A 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists Abandoned AU2020329290A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886148P 2019-08-13 2019-08-13
US62/886,148 2019-08-13
PCT/US2020/046244 WO2021030633A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Publications (1)

Publication Number Publication Date
AU2020329290A1 true AU2020329290A1 (en) 2022-03-24

Family

ID=72243240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020329290A Abandoned AU2020329290A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Country Status (8)

Country Link
US (1) US20230002466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013774A1 (cg-RX-API-DMAC7.html)
JP (2) JP7783164B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044534A (cg-RX-API-DMAC7.html)
CN (1) CN114787182A (cg-RX-API-DMAC7.html)
AU (1) AU2020329290A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147677A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021030633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
EP4373848A2 (en) * 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
WO2023220597A1 (en) * 2022-05-10 2023-11-16 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2016126719A1 (en) * 2015-02-03 2016-08-11 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists

Also Published As

Publication number Publication date
JP2022544785A (ja) 2022-10-21
WO2021030633A1 (en) 2021-02-18
CN114787182A (zh) 2022-07-22
JP7783164B2 (ja) 2025-12-09
CA3147677A1 (en) 2021-02-18
US20230002466A1 (en) 2023-01-05
KR20220044534A (ko) 2022-04-08
JP2026032136A (ja) 2026-02-25
EP4013774A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
JP7783164B2 (ja) 改変インターロイキン2受容体ベータアゴニスト
US11208459B2 (en) Constructs having a SIRP-alpha domain or variant thereof
JP7098725B2 (ja) 二重特異性2+1コントースボディ
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP7148539B2 (ja) 免疫抱合体
JP6464255B2 (ja) 二重特異性t細胞活性化抗原結合分子
CN103492411B (zh) 突变体白介素-2多肽
JP2021528988A (ja) 新規の二重特異性アゴニスト4−1bb抗原結合分子
US20240376171A1 (en) Protease-activated polypeptides
JP2025500949A (ja) アゴニストltbr抗体及びそれらを含む二重特異性抗体
CN121021670A (zh) Ctla-4变体免疫调节蛋白和其用途
AU2021393752A1 (en) Ph-dependent mutant interleukin-2 polypeptides
WO2023081959A1 (en) Immunotherapeutic proteins comprising an fc region component with a mutation at position 429
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
HK40076453A (en) Engineered interleukin-2 receptor beta agonists
HK40102926A (en) Bispecific antibodies with charge pairs and uses thereof
CN118510802A (zh) Cd20-pd1结合分子及其使用方法
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
HK1257372B (en) Constructs having a sirp-alpha domain or variant thereof